ADVERTISEMENT
Torrent Pharma Q4 Review: Motilal Oswal Maintains 'Neutral', Says Current Valuation Factors In Earnings Upside
Motilal Oswal maintains 'Neutral' stance on Torrent Pharma, but hikes target price
21 May 2025, 09:17 AM IST 
Save
Torrent Pharma's India formulations revenue grew 12% YoY to Rs 15.5 billion. US generics grew 15.3% YoY to Rs 3 billion. (Photo Source: Freepik)
Torrent Pharma is readying itself to be in the first wave of launch of Semaglutide in India market. Its Curatio portfolio grew 18-19% YoY in FY25 and aspires to grow this business at higher rate in coming year. Torrent Pharma’s chronic portfolio in DF market grew 14% vs industry growth of 9% for the quarter.
